What is launch excellence?
A successful pharmaceutical launch is more than just introducing a new product. It requires strategic execution, cross-functional collaboration, and continuous adaptation to ensure long-term impact. Despite extensive planning, many drug launches fail to meet market expectations, with over a third of new therapies struggling to gain traction in their first year.
The key to overcoming these challenges? Launch excellence.
Launch excellence is the ability to minimize risks and maximize opportunities at every stage of the product lifecycle. It requires a proactive approach that aligns medical affairs and commercial teams, leverages real-time insights, and ensures strong engagement with key stakeholders, from physicians and payers to patients and digital influencers.
Why do pharmaceutical launches fail?
In 2014, McKinsey reported that as many as two-thirds of pharmaceutical launches missed their pre-launch sales targets. More than a decade later, even with dramatic strides in science and technology, the industry continues to wrestle with launch underperformance.
Common pitfalls include:
- Lack of actionable insights: Without timely, high-quality feedback from HCPs, KOLs, and patients, commercial teams struggle to refine messaging and optimize launch positioning.
- Regulatory and market access hurdles: Unanticipated delays, pricing restrictions, and reimbursement challenges can significantly slow market adoption.
- Ineffective stakeholder engagement: Failing to build advocacy among physicians, KOLs, and digital opinion leaders (DOLs) can result in slower uptake and lower prescriber confidence.
- Disjointed commercialization efforts: When medical and commercial teams operate in silos, inconsistent messaging and misaligned strategies can limit a product’s market penetration.
The good news is that most launch failures aren’t inevitable. Many can be traced to preventable gaps in planning, execution, and alignment. By building on a unified data foundation, organizations can close those gaps, strengthen decision-making, and improve launch outcomes.
How pharma teams achieve launch excellence
According to reporting from Bain & Company, pharma organizations that pull off successful launches do these three things:
- Differentiate their therapy with messaging, post-launch data, and patient services
- Build customer advocacy by providing a good consumer experience
- View a drug launch as a “micro-battle” and solicit ongoing feedback from field teams
However, if you’ve ever worked on a launch, you know these goals require more than just good intentions. To avoid pitfalls, leading pharma teams are increasingly turning to integrated, insights-driven solutions that allow them to execute faster and smarter at every stage of a launch.
Here’s how they are doing it.
1. Train teams for strategic execution
Virtual collaboration and training platforms help medical affairs and commercial teams stay aligned on strategy, messaging, and stakeholder engagement—ensuring agility when challenges arise.
Asynchronous virtual engagement provides an effective way to train global launch teams efficiently, regardless of location or time zone. Additionally, live, in-conversation translation ensures that MSLs across territories can fully engage in discussions and training sessions in their native language, improving knowledge retention and alignment.
2. Define market-specific benchmarks
Generic performance metrics often fail to capture the nuances of specific disease areas, patient pathways, and prescribing behaviors. Instead, successful pharma teams leverage real-time market intelligence to define more accurate benchmarks.
3. Use insights to refine messaging
Launch excellence requires messaging that resonates with both physicians and patients. Pre-launch message testing and real-time feedback help teams refine clinical differentiation strategies and brand positioning, ensuring a stronger impact from day one.
Social listening extends this feedback loop by capturing ongoing insights from HCPs, patients, and KOLs. With AI-powered analytics, teams can rapidly identify and act on these signals to deploy updated messaging strategies in days instead of months.
4. Integrate patient perspectives
Patient feedback is essential for launch excellence. Insights into treatment experiences, adherence barriers, and decision-making factors provide actionable data that pharma teams can translate into more effective launch strategies that drive better outcomes for patients, HCPs, and companies alike.
Medical affairs teams play a pivotal role in embedding these insights into strategy, ensuring a truly patient-centric approach that strengthens engagement and supports long-term adoption.
5. Engage physicians early and often
Physicians not only prescribe treatments—they influence peer adoption and treatment guidelines. Structured engagement through advisory boards, social listening, and ongoing discussions helps pharma teams capture meaningful insights on prescribing behaviors, competitive perceptions, and clinical challenges.
Medical congresses remain critical touchpoints for HCP engagement and launch visibility. Pharma teams can enhance their congress strategies by implementing agile, virtual collaboration methods that allow key stakeholders to share findings, track discussions, and update launch strategies in real time.
Related: Learn how one medical affairs team used virtual congress huddles to gain invaluable HCP insights.
6. Identify emerging KOLs and DOLs
Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs) play an increasingly important role in shaping perceptions of new therapies. While KOLs drive scientific credibility within professional networks, DOLs expand digital reach, influencing both HCP and patient decision-making. Leading pharma teams are combining traditional KOL mapping with social listening to identify the most impactful voices and optimize engagement strategies.
7. Foster cross-functional collaboration
Improving alignment across medical affairs and commercial teams is one of the most effective ways to improve launch execution and efficiency. Real-time insights and cross-functional collaboration platforms ensure that both teams work with a shared understanding of market conditions, customer feedback, and strategic goals.
8. Streamline publication planning and creation
Publications are essential for educating stakeholders and shaping the scientific narrative around new therapies. However, publication planning and content development are often time-consuming and resource-intensive.
Pharma teams can streamline publication development with collaborative digital tools that enable real-time co-authoring, review, and editing. This reduces the number of drafts required, eliminates inefficiencies from email-based collaboration, and allows teams to produce high-quality, impactful publications on a faster timeline—supporting both scientific engagement and market education.
9. Gather continuous feedback and adapt
A successful launch isn’t just about the first 90 days—it requires ongoing learning and adaptation. Leading pharma companies are investing in real-time insights management platforms to track launch performance, capture stakeholder feedback, and make data-driven adjustments before small issues become major obstacles.
Set the stage for excellence with Launch Intelligence™
Launch excellence is more than a milestone—it’s a repeatable, scalable framework that ensures every product reaches its full potential. Pharma companies must embrace technology, real-time insights, and cross-functional collaboration to overcome common launch challenges and drive long-term success.
Launching new products is a golden opportunity to try out new techniques and gauge their impact before rolling them out more widely. Given the uncertainties triggered by the pandemic and the radical changes in physicians’ preferences and behaviors, replicating successful launch strategies from the past is no longer a safe option.
– McKinsey
Is your team equipped for a successful launch?
Schedule a demo to see how the Within3 Launch Intelligence™ platform transforms data into actionable insights.
Sources
Atrivity. Why lack of attention to detail is killing pharma launches. https://blog.atrivity.com/lack-of-detail-killing-pharma-launches#:~:text=Most%20product%20launch%20disasters%20are,been%20prevented%20with%20better%20planning.
Bain & Company. How to make your drug launch a success. https://www.bain.com/insights/how-to-make-your-drug-launch-a-success/
Deloitte. Key factors to improve drug launches. https://www2.deloitte.com/us/en/insights/industry/life-sciences/successful-drug-launch-strategy.html
Health Advances. Launch Excellence. https://healthadvances.com/launch-excellence/
McKinsey. Launch excellence: everything depends on flawless operations. https://www.mckinsey.com/business-functions/operations/our-insights/launch-excellence-everything-depends-on-flawless-operations
McKinsey & Company. Ready for launch: Reshaping pharma’s strategy in the next normal. https://www.mckinsey.com/industries/life-sciences/our-insights/ready-for-launch-reshaping-pharmas-strategy-in-the-next-normal
Oxford. Crossing the Pharma Chasm – Why do Pharma Launches Fail? https://oxfordsm.com/oxfordsm-insights/events-articles/2020/why-do-pharma-launches-fail
